Benjamin R. Bellenie

London, ENG SM25NG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Towards the Rational Design of Monovalent Degraders: Lessons Learnt from Cyclin K Degraders.

Towards the Rational Design of Monovalent Degraders: Lessons Learnt from Cyclin K Degraders.

Journal: Chimia

Published: January 15, 2025

RIPK1 is essential for Herpes Simplex Virus-triggered ZBP1-dependent necroptosis in human cells.

RIPK1 is essential for Herpes Simplex Virus-triggered ZBP1-dependent necroptosis in human cells.

Journal: bioRxiv : the preprint server for biology

Published: September 30, 2024

The Chemical Probes Portal - 2024: update on this public resource to support best-practice selection and use of small molecules in biomedical research.

The Chemical Probes Portal - 2024: update on this public resource to support best-practice selection and use of small molecules in biomedical research.

Journal: Nucleic acids research

Published: September 14, 2024

RIPK1 is required for ZBP1-driven necroptosis in human cells.

RIPK1 is required for ZBP1-driven necroptosis in human cells.

Journal: PLoS biology

Published: August 29, 2024

Specific radiation damage to halogenated inhibitors and ligands in protein-ligand crystal structures.

Specific radiation damage to halogenated inhibitors and ligands in protein-ligand crystal structures.

Journal: Journal of applied crystallography

Published: May 09, 2024

Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors.

Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors.

Journal: ACS chemical biology

Published: January 09, 2024

Determination of Ligand-Binding Affinity (Kd) Using Transverse Relaxation Rate (R2) in the Ligand-Observed 1H NMR Experiment and Applications to Fragment-Based Drug Discovery.

Determination of Ligand-Binding Affinity (Kd) Using Transverse Relaxation Rate (R2) in the Ligand-Observed 1H NMR Experiment and Applications to Fragment-Based Drug Discovery.

Journal: Journal of medicinal chemistry

Published: July 19, 2023

A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.

A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.

Journal: Immunity

Published: July 10, 2023

Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones.

Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones.

Journal: Journal of medicinal chemistry

Published: April 07, 2023

Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays.

Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays.

Journal: Scientific reports

Published: July 04, 2022

Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.

Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.

Journal: Journal of medicinal chemistry

Published: June 03, 2022

Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo.

Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo.

Journal: Journal of medicinal chemistry

Published: June 02, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026